Skip to content

AEON Biopharma, Inc.: 10-Q filed 2023-07-21

What AEON Biopharma, Inc. reported in its quarterly report filed 2023-07-21 (fiscal Q2 2023): 17 published measures, 51 facts as tagged in accession 0001104659-23-082959.

This filing

Form
10-Q (quarterly report)
Filed
2023-07-21
Fiscal period
fiscal Q2 2023
Accession
0001104659-23-082959 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AEON Biopharma, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-06-3021,785,493USD
At 2022-12-31279,493,625USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-06-3012,053,282USD
At 2022-12-3110,443,306USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-06-30-11,461,184USD
At 2023-03-31-7,317,951USD
At 2022-12-31-9,436,953USD
At 2022-06-30-12,369,045USD
At 2022-03-31-14,156,462USD
At 2021-12-31-16,929,855USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-3,942,337USD91
2023-01-01 to 2023-06-30-4,330,852USD181
2023-01-01 to 2023-03-31-388,515USD90
2022-04-01 to 2022-06-301,867,104USD91
2022-01-01 to 2022-06-304,640,497USD181
2022-01-01 to 2022-03-312,773,393USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-1,569,985USD181
2022-01-01 to 2022-06-30-570,154USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-258,149,909USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-06-30260,093,362USD181
2022-01-01 to 2022-06-3080,500USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-06-30-11,493,874USD
At 2022-12-31-9,469,643USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2023-04-01 to 2023-06-3091,662USD91
2023-01-01 to 2023-06-30496,296USD181
2022-04-01 to 2022-06-3016,965USD91
2022-01-01 to 2022-06-3016,965USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-3,526,521USD91
2023-01-01 to 2023-06-30-5,270,006USD181
2022-04-01 to 2022-06-30-427,204USD91
2022-01-01 to 2022-06-30-816,277USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-06-30592,098USD
At 2022-12-31109,196USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-06-309,460,757USD
At 2022-12-313,880,947USD

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-06-30441,377USD
At 2022-12-3167,909USD
At 2022-06-307,758USD
At 2021-12-31497,412USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-06-3032,000USD
At 2022-12-3132,000USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-3,850,675USD91
2023-01-01 to 2023-06-30-3,834,556USD181
2022-04-01 to 2022-06-301,884,069USD91
2022-01-01 to 2022-06-304,657,462USD181

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-4,330,852USD181
2022-01-01 to 2022-06-304,640,497USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-324,154USD91
2023-01-01 to 2023-06-301,435,450USD181
2022-04-01 to 2022-06-302,311,273USD91
2022-01-01 to 2022-06-305,473,739USD181

Inspect the source

Entity
AEON Biopharma, Inc. / CIK 0001837607
Captured
2026-09-21T17:29:50.996Z
SEC response SHA-256
976029d82f5d8e8df46acac5fd0f8f0502e669de4260fc049cc4fa8c20c63230

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001837607.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))